Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Giuseppe Murdaca, Simone Negrini, Monica Greco, Chiara Schiavi, Francesca Giusti, Matteo Borro & Francesco Puppo. (2019) Immunogenicity of infliximab and adalimumab. Expert Opinion on Drug Safety 18:5, pages 343-345.
Read now
Read now
Mario Fernández-Ruiz & José María Aguado. (2018) Risk of infection associated with anti-TNF-α therapy. Expert Review of Anti-infective Therapy 16:12, pages 939-956.
Read now
Read now
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich & Francesco Puppo. (2018) Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Modern Rheumatology 28:3, pages 417-431.
Read now
Read now
J. M. Carrascosa & E. Del-Alcazar. (2018) New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology 14:4, pages 259-273.
Read now
Read now
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio & Francesco Puppo. (2017) Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opinion on Drug Safety 16:10, pages 1173-1179.
Read now
Read now
Buraa Kubaisi, Sarah Syeda, Alexander Schmidt & C. Stephen Foster. (2017) Adalimumab for the treatment of non-infectious uveitis: an updated review. Expert Opinion on Orphan Drugs 5:2, pages 201-206.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Elena Penza, Ottavia Magnani & Francesco Puppo. (2016) Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. Expert Opinion on Drug Safety 15:1, pages 43-52.
Read now
Read now
Luciane Cruz Lopes, Miriam Sanches do Nascimento Silveira, Mayara Costa de Camargo, Iara Alves de Camargo, Tatiana Chama Borges Luz, Claudia Garcia Serpa Osorio-de-Castro, Silvio Barberato-Filho, Fernando de Sá Del Fiol & Gordon Guyatt. (2014) Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil. Expert Opinion on Drug Safety 13:9, pages 1155-1163.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Ottavia Magnani & Francesco Puppo. (2014) Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opinion on Drug Safety 13:5, pages 649-661.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò & Francesco Puppo. (2014) Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opinion on Drug Safety 13:3, pages 295-305.
Read now
Read now
Hong Yang & Arthur Kavanaugh. (2014) Adverse effects of golimumab in the treatment of rheumatologic diseases. Expert Opinion on Drug Safety 13:1, pages 103-112.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò & Francesco Puppo. (2013) Long-term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatology: Research and Reviews 5, pages 43-49.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò & Francesco Puppo. (2013) Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opinion on Drug Safety 12:6, pages 801-804.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò, Paola Cagnati & Francesco Puppo. (2013) Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors. Redox Report 18:3, pages 95-99.
Read now
Read now
Articles from other publishers (31)
Masanao Kyuuma, Ayaka Kaku, Chiemi Mishima-Tsumagari, Bunichiro Ogawa, Mayumi Endo, Yunoshin Tamura, Kei-ichiro Ishikura, Masashi Mima, Yutaka Nakanishi & Yasuyuki Fujii. (2023) Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation. Frontiers in Immunology 14.
Crossref
Crossref
Timothy G. Chow, Lauren E. Franzblau & David A. Khan. (2022) Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases. Current Allergy and Asthma Reports 22:12, pages 195-207.
Crossref
Crossref
Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He & Qilin Zhang. (2022) Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Frontiers in Pharmacology 13.
Crossref
Crossref
Terri Shih, Devea R. De, Vivian Y. Shi & Jennifer L. Hsiao. (2022) Biologics and small molecule inhibitors for hidradenitis suppurativa. Dermatological Reviews 3:2, pages 98-110.
Crossref
Crossref
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa & Fabiana Zingone. (2022) Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intestinal Research 20:1, pages 114-123.
Crossref
Crossref
Sevim Bavbek, Mauro Pagani, Emilio Alvarez‐Cuesta, Mariana Castells, Adile Berna Dursun, Sahar Hamadi, Ricardo Madrigal‐Burgaleta, Soledad Sanchez‐Sanchez & Alessandra Vultaggio. (2021) Hypersensitivity reactions to biologicals: An EAACI position paper. Allergy 77:1, pages 39-54.
Crossref
Crossref
Karen J. L. Choo & Yi Wei Yeo. 2022. Drug Eruptions. Drug Eruptions
283
302
.
Jamie L. Waldron, Stephen A. Schworer & Mildred Kwan. (2021) Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clinical Reviews in Allergy & Immunology 62:3, pages 413-431.
Crossref
Crossref
Virginia L. Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari, Kathleen A. Day & Angelo Camporeale. (2020) Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine. BMC Neurology 20:1.
Crossref
Crossref
Anja St Clair-Jones, Francesca Prignano, Joao Goncalves, Muriel Paul & Philipp Sewerin. (2020) Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. Rheumatology and Therapy 7:4, pages 741-757.
Crossref
Crossref
Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi & Alan Menter. (2019) Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatology and Therapy 10:1, pages 99-106.
Crossref
Crossref
Urmi Khanna, Ariana M. Ellis & Anthony P. Fernandez. (2019) Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases. Current Treatment Options in Rheumatology 5:4, pages 290-312.
Crossref
Crossref
Mayara Costa de Camargo, Bruna Cipriano Almeida Barros, Izabela Fulone, Marcus Tolentino Silva, Miriam Sanches do Nascimento Silveira, Iara Alves de Camargo, Silvio Barberato-Filho, Fernando de Sá Del Fiol & Luciane Cruz Lopes. (2019) Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Frontiers in Pharmacology 10.
Crossref
Crossref
Giuseppe Murdaca, Alessandro Tonacci, Simone Negrini, Monica Greco, Matteo Borro, Francesco Puppo & Sebastiano Gangemi. (2019) Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. Autoimmunity Reviews 18:9, pages 102350.
Crossref
Crossref
Karolina Vorčáková, Tatiana Péčová, Klára Martinásková, Katarína Nováčeková & Juraj Péč. 2019. Tailored Treatments in Psoriatic Patients. Tailored Treatments in Psoriatic Patients.
Khaled Ezzedine, Laetitia Visseaux, Guillaume Cadiot, Hedia Brixi, Philippe Bernard & Ziad Reguiai. (2019) Ustekinumab for skin reactions associated with anti‐tumor necrosis factor‐α agents in patients with inflammatory bowel diseases: A single‐center retrospective study. The Journal of Dermatology 46:4, pages 322-327.
Crossref
Crossref
Yihe Chen & Kuifen Ma. (2019) NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease. Biochemical and Biophysical Research Communications 511:3, pages 524-530.
Crossref
Crossref
Steven Ramael, Benjamin Van Hoorick, Renger Tiessen, Thijs van Iersel, Viktoria Moschetti, Benjamin Lang, Ivo Sonderegger, Sabrina Wiebe, Bernd Liedert & Girish Jayadeva. (2018) Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials. Rheumatology and Therapy 5:2, pages 403-421.
Crossref
Crossref
Floriane Groell, Olivier Jordan & Gerrit Borchard. (2018) In vitro models for immunogenicity prediction of therapeutic proteins. European Journal of Pharmaceutics and Biopharmaceutics 130, pages 128-142.
Crossref
Crossref
Brian C. Tse, Galina Dvoriantchikova, Wensi Tao, Ryan A. Gallo, John Y. Lee, Steven Pappas, Roberta Brambilla, Dmitry Ivanov, David T. Tse & Daniel Pelaez. (2018) Tumor Necrosis Factor Inhibition in the Acute Management of Traumatic Optic Neuropathy. Investigative Opthalmology & Visual Science 59:7, pages 2905.
Crossref
Crossref
Floriane Groell, Yogeshvar N. Kalia, Olivier Jordan & Gerrit Borchard. (2018) Hydrogels in three-dimensional dendritic cell (MUTZ-3) culture as a scaffold to mimic human immuno competent subcutaneous tissue. International Journal of Pharmaceutics 544:1, pages 297-303.
Crossref
Crossref
Philip H. Li, Timothy J. Watts, Mei-Shan Lui, Chak-Sing Lau & Ho-Yin Chung. (2018) Recall Urticaria in Adalimumab Hypersensitivity. The Journal of Allergy and Clinical Immunology: In Practice 6:3, pages 1032-1033.
Crossref
Crossref
Matthew P. Baker, Timothy D. Jones & Paul Chamberlain. 2017. Protein Therapeutics. Protein Therapeutics
387
421
.
Paul Chamberlain. 2017. Biosimilar Drug Product Development. Biosimilar Drug Product Development
323
360
.
Jeffrey A. Willy, Nanette E. Schulte, Emiko L. Kreklau, Jennie L. Walgren, Matthew L. Renninger & Thomas K. Baker. (2016)
In Vitro
L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules
. Toxicological Sciences 151:2, pages 302-311.
Crossref
Crossref
Xiao Hu, Fang Yuan, Jian Zhang, Lei Yin, Bi-Ru Li & Yan-Liang Jin. (2015) Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis. World Journal of Pediatrics 12:1, pages 96-102.
Crossref
Crossref
Giuseppe Murdaca, Rodolfo Russo, Francesca Spanò, Diego Ferone, Manuela Albertelli, Angelo Schenone, Miriam Contatore, Andrea Guastalla, Annamaria De Bellis, Giacomo Garibotto & Francesco Puppo. (2015) Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. Archives of Endocrinology and Metabolism 59:6, pages 554-558.
Crossref
Crossref
Maria A.V. Willrich, David L. Murray & Melissa R. Snyder. (2015) Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Translational Research 165:2, pages 270-282.
Crossref
Crossref
Giuseppe Murdaca, Rossella Gulli, Francesca Spanò, Paola Mandich & Francesco Puppo. (2014) Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?. Drug Development Research 75, pages S7-S10.
Crossref
Crossref
Alessandra Vultaggio & Mariana C. Castells. (2014) Hypersensitivity Reactions to Biologic Agents. Immunology and Allergy Clinics of North America 34:3, pages 615-632.
Crossref
Crossref
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla & Francesco Puppo. (2014) Potential use of TNF-α inhibitors in systemic sclerosis. Immunotherapy 6:3, pages 283-289.
Crossref
Crossref